Company: SNPS
Filing Date: 2025-07-17
Form Type: 425
Source: 0001140361-25-026140
Chunk: 6

Company: SYNOPSYS INC
Filing Date: 2025-07-17
Form: 425
Chunk 6
---
 shares of Synopsys common stock with a grant date fair market value of $350,000, which will vest in equal installments on the date immediately preceding each of the first three annual meetings following the date of grant, subject to continued Board service through each vesting date; and (ii) an interim restricted stock award for shares of Synopsys common stock with a grant date fair market value equal to a prorated portion of the annual award of $200,000, which will vest on the date immediately preceding the first annual meeting following the date of grant. Neither Dr. Gopal nor Mr. Vijayaraghavan have any family relationship with any of Synopsys’ directors or executive officers or any persons nominated or chosen by Synopsys to be a director or executive officer. Furthermore, neither Dr. Gopal nor Mr. Vijayaraghavan have any direct or indirect material interest in any transaction or proposed transaction required to be reported under Section 404(a) of Regulation S-K other than consideration received in connection with the Merger in accordance with the terms of the Merger Agreement. In accordance with Synopsys’ customary practice, Synopsys is entering into its standard form of indemnification agreement with each of Dr. Gopal and Mr. Vijayaraghavan, which requires Synopsys to indemnify Dr. Gopal and Mr. Vijayaraghavan against certain liabilities that may arise as result of their status or service as directors. The description of Dr. Gopal’s and Mr. Vijayaraghavan’s indemnification agreements is qualified in its entirety by the full text of the form of indemnification agreement, which is attached to Synopsys’ Form 8-K filed on July 14, 2011, as Exhibit 99.2. In connection with the Merger, immediately following the Effective Time, Janet Lee, Senior Vice President, General Counsel and Secretary of Ansys was appointed as Synopsys’ General Counsel and Corporate Secretary, succeeding John F. Runkel, Jr. in these positions. Mr. Runkel transitioned to the advisory role of Chief Legal Officer, and will continue in that role until January 31, 2026 (or such later date, as determined by Synopsys) to ensure a smooth transition. Mr. Runkel’s departure is a qualifying termination under Synopsys’ Executive Severance Benefit and Transition Plan such that he will be entitled to all the benefits set forth therein, subject to his execution of a separation and release agreement and compliance